Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 115

1.

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.

Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit VTHBM, Nout RA; PORTEC Study Group.

Br J Cancer. 2018 Oct;119(9):1067-1074. doi: 10.1038/s41416-018-0310-8. Epub 2018 Oct 25.

PMID:
30356126
2.

Cancer of the corpus uteri.

Amant F, Mirza MR, Koskas M, Creutzberg CL.

Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:37-50. doi: 10.1002/ijgo.12612.

PMID:
30306580
3.

Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions.

De Boer SM, Nout RA, Bosse T, Creutzberg CL.

Expert Rev Anticancer Ther. 2018 Oct 24:1-10. doi: 10.1080/14737140.2019.1531708. [Epub ahead of print]

PMID:
30295094
4.

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.

Wortman BG, Bosse T, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld H, van den Berg H, Slot A, De Winter KAJ, Verhoeven-Adema KW, Smit VTHBM, Creutzberg CL; PORTEC Study Group.

Gynecol Oncol. 2018 Oct;151(1):69-75. doi: 10.1016/j.ygyno.2018.07.020. Epub 2018 Aug 3.

5.

ESGO Survey on Current Practice in the Management of Cervical Cancer.

Dostalek L, Åvall-Lundqvist E, Creutzberg CL, Kurdiani D, Ponce J, Dostalkova I, Cibula D.

Int J Gynecol Cancer. 2018 Jul;28(6):1226-1231. doi: 10.1097/IGC.0000000000001314.

PMID:
29958236
6.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.

Auguste A, Genestie C, De Bruyn M, Adam J, Le Formal A, Drusch F, Pautier P, Crosbie EJ, MacKay H, Kitchener HC, Powell M, Pollock PM, Mileshkin L, Edmondson RJ, Nout R, Nijman HW, Creutzberg CL, Bosse T, Leary A.

Mod Pathol. 2018 Dec;31(12):1851-1861. doi: 10.1038/s41379-018-0055-1. Epub 2018 Jun 28.

PMID:
29955143
7.

Differences in health care professionals' and cancer patients' views on sexual health issues.

Greimel E, Lanceley A, Oberguggenberger A, Nordin A, Kuljanic K, Schmalz C, Arraras JI, Chie W, Jensen PT, Tomaszewski KA, Creutzberg CL, Galalae R, Toelen H, Inwald EC, Bjelic-Radisic V; EORTC Quality of Life Group.

Psychooncology. 2018 Sep;27(9):2299-2302. doi: 10.1002/pon.4814. Epub 2018 Jul 3. No abstract available.

PMID:
29927000
8.

Investigators' response.

Nout RA, Powell ME, de Boer SM, Creutzberg CL.

Lancet Oncol. 2018 May;19(5):602. doi: 10.1016/S1470-2045(18)30279-1. No abstract available.

PMID:
29726377
9.

Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?

Creutzberg CL, Bosse T.

Ann Oncol. 2018 May 1;29(5):1081-1082. doi: 10.1093/annonc/mdy098. No abstract available.

PMID:
29668827
10.

ENdometrial cancer SURvivors' follow-up carE (ENSURE): Less is more? Evaluating patient satisfaction and cost-effectiveness of a reduced follow-up schedule: study protocol of a randomized controlled trial.

Ezendam NPM, de Rooij BH, Kruitwagen RFPM, Creutzberg CL, van Loon I, Boll D, Vos MC, van de Poll-Franse LV.

Trials. 2018 Apr 16;19(1):227. doi: 10.1186/s13063-018-2611-x.

11.

Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues.

Van Gool IC, Rayner E, Osse EM, Nout RA, Creutzberg CL, Tomlinson IPM, Church DN, Smit VTHBM, de Wind N, Bosse T, Drost M.

Clin Cancer Res. 2018 Jul 1;24(13):3197-3203. doi: 10.1158/1078-0432.CCR-18-0266. Epub 2018 Mar 20.

PMID:
29559562
12.

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

13.

Phase 1-3 of the cross-cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ-22.

Oberguggenberger AS, Nagele E, Inwald EC, Tomaszewski K, Lanceley A, Nordin A, Creutzberg CL, Kuljanic K, Kardamakis D, Schmalz C, Arraras J, Costantini A, Almont T, Wei-Chu C, Dehandschutter S, Winters Z, Greimel E; EORTC Quality of Life Group.

Cancer Med. 2018 Mar;7(3):635-645. doi: 10.1002/cam4.1338. Epub 2018 Feb 13.

14.

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.

de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM; for PORTEC Study Group.

Ann Oncol. 2018 Feb 1;29(2):424-430. doi: 10.1093/annonc/mdx753.

15.

International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

van de Poll-Franse L, Oerlemans S, Bredart A, Kyriakou C, Sztankay M, Pallua S, Daniëls L, Creutzberg CL, Cocks K, Malak S, Caocci G, Molica S, Chie W, Efficace F; EORTC Quality of Life Group.

Qual Life Res. 2018 Feb;27(2):333-345. doi: 10.1007/s11136-017-1718-y. Epub 2017 Nov 10.

16.

Ruthenium-106 brachytherapy for iris and iridociliary melanomas.

Marinkovic M, Horeweg N, Laman MS, Bleeker JC, Ketelaars M, Peters FP, Luyten GPM, Creutzberg CL.

Br J Ophthalmol. 2018 Aug;102(8):1154-1159. doi: 10.1136/bjophthalmol-2017-310688. Epub 2017 Nov 9.

PMID:
29122824
17.

Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma.

Depreeuw J, Stelloo E, Osse EM, Creutzberg CL, Nout RA, Moisse M, Garcia-Dios DA, Dewaele M, Willekens K, Marine JC, Matias-Guiu X, Amant F, Lambrechts D, Bosse T.

Clin Cancer Res. 2017 Dec 1;23(23):7232-7241. doi: 10.1158/1078-0432.CCR-17-0566. Epub 2017 Sep 22.

18.

Corrigendum to "Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification" [Eur J Cancer 78 (2017) 82-90].

Eggink FA, Mom CH, Bouwman K, Boll D, Becker JH, Creutzberg CL, Niemeijer GC, van Driel WJ, Reyners AK, van der Zee AG, Bremer GL, Ezendam NP, Kruitwagen RF, Pijnenborg JM, Hollema H, Nijman HW, van der Aa MA.

Eur J Cancer. 2017 Oct;84:370. doi: 10.1016/j.ejca.2017.08.003. Epub 2017 Aug 23. No abstract available.

PMID:
28844347
19.

Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.

Van Gool IC, Ubachs JEH, Stelloo E, de Kroon CD, Goeman JJ, Smit VTHBM, Creutzberg CL, Bosse T.

Histopathology. 2018 Jan;72(2):248-258. doi: 10.1111/his.13338. Epub 2017 Oct 10.

PMID:
28795426
20.

Reply to M. Wissing et al.

Wiltink LM, Nout RA, Fiocco M, Creutzberg CL, Marijnen CAM.

J Clin Oncol. 2017 Jun 1;35(16):1862. doi: 10.1200/JCO.2017.72.6125. Epub 2017 Mar 13. No abstract available.

PMID:
28549229

Supplemental Content

Loading ...
Support Center